Nuvilex Inc. (NASDAQ:PMCB) Short Interest Update

Nuvilex Inc. (NASDAQ:PMCB) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totaling 177,318 shares, an increase of 181.9% from the December 31st total of 62,893 shares. Approximately 2.0% of the company’s shares are sold short. Based on an average trading volume of 459,349 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 459,349 shares, the short-interest ratio is presently 0.4 days. Approximately 2.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Insider Transactions at Nuvilex

In related news, CEO Joshua Silverman acquired 40,000 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was acquired at an average cost of $0.83 per share, for a total transaction of $33,200.00. Following the acquisition, the chief executive officer owned 416,250 shares of the company’s stock, valued at $345,487.50. This trade represents a 10.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have acquired 110,000 shares of company stock worth $89,000. 10.33% of the stock is currently owned by insiders.

Nuvilex Trading Down 5.2%

PMCB opened at $0.90 on Thursday. The company has a market cap of $9.11 million, a price-to-earnings ratio of -0.65 and a beta of 0.04. The stock has a fifty day simple moving average of $0.86 and a two-hundred day simple moving average of $0.93. Nuvilex has a 12-month low of $0.63 and a 12-month high of $1.90.

Nuvilex (NASDAQ:PMCB) last released its earnings results on Thursday, December 18th. The company reported ($0.32) earnings per share for the quarter.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.